相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The predictive value of the prostate health index vs. multiparametric magnetic resonance imaging for prostate cancer diagnosis in prostate biopsy
Jiri Stejskal et al.
WORLD JOURNAL OF UROLOGY (2021)
Using biomarkers in patients with positive multiparametric magnetic resonance imaging: 4Kscore predicts the presence of cancer outside the index lesion
Ugo Giovanni Falagario et al.
INTERNATIONAL JOURNAL OF UROLOGY (2021)
Use of the MyProstateScore Test to Rule Out Clinically Significant Cancer: Validation of a Straightforward Clinical Testing Approach
Jeffrey J. Tosoian et al.
JOURNAL OF UROLOGY (2021)
Performance of Prostate Health Index in Biopsy Naive Black Men
Rilwan Babajide et al.
JOURNAL OF UROLOGY (2021)
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent
Nicolas Mottet et al.
EUROPEAN UROLOGY (2021)
Combining prostate health index and multiparametric magnetic resonance imaging in the diagnosis of clinically significant prostate cancer in an Asian population
Po-Fan Hsieh et al.
WORLD JOURNAL OF UROLOGY (2020)
Cancer statistics, 2020
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2020)
The Four-Kallikrein Panel Is Effective in Identifying Aggressive Prostate Cancer in a Multiethnic Population
Burcu F. Darst et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2020)
Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2-10 ng/mL
Ronald Tutrone et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2020)
Prespecified 4-Kallikrein Marker Model at Age 50 or 60 for Early Detection of Lethal Prostate Cancer in a Large Population Based Cohort of Asymptomatic Men Followed for 20 Years
Emily A. Vertosick et al.
JOURNAL OF UROLOGY (2020)
Liquid Biopsy as Novel Tool in Precision Medicine: Origins, Properties, Identification and Clinical Perspective of Cancer's Biomarkers
Diego Fernandez-Lazaro et al.
DIAGNOSTICS (2020)
Effects of replacing PSA with Stockholm3 for diagnosis of clinically significant prostate cancer in a healthcare system - the Stavanger experience
Eirik Viste et al.
SCANDINAVIAN JOURNAL OF PRIMARY HEALTH CARE (2020)
A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy
James McKiernan et al.
BMC UROLOGY (2020)
Use of the Prostate Health Index and Density in 3 Outpatient Centers to Avoid Unnecessary Prostate Biopsies
Anni Schulze et al.
UROLOGIA INTERNATIONALIS (2020)
The Cost of Prostate Biopsies and their Complications: A Summary of Data on All Medicare Fee-for-Service Patients over 2 Years
Adam B. Weiner et al.
UROLOGY PRACTICE (2020)
Avoiding Unnecessary Magnetic Resonance Imaging (MRI) and Biopsies: Negative and Positive Predictive Value of MRI According to Prostate-specific Antigen Density, 4Kscore and Risk Calculators
Ugo Giovanni Falagario et al.
EUROPEAN UROLOGY ONCOLOGY (2020)
Diagnostic accuracy of prostate cancer antigen 3 (PCA3) prior to first prostate biopsy: A systematic review and meta-analysis
Sandra Viviana Munoz Rodriguez et al.
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL (2020)
Evaluation of an Epigenetic Assay for Predicting Repeat Prostate Biopsy Outcome in African American Men
Robert L. Waterhouse et al.
UROLOGY (2019)
Cost-effectiveness of SelectMDx for prostate cancer in four European countries: a comparative modeling study
Tim M. Govers et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2019)
The Stockholm3 blood-test predicts clinically-significant cancer on biopsy: independent validation in a multi-center community cohort
Axel Moller et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2019)
Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore
Jan F. M. Verbeek et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2019)
Re: Optimizing Patient's Selection for Prostate Biopsy: A Single Institution Experience with Multi-parametric MRI and the 4Kscore Test for the Detection of Aggressive Prostate Cancer Punnen S, Nahar B, Soodana Prakash N, et al PLoS One 2018;371:e0201384
David Margel et al.
EUROPEAN UROLOGY (2019)
Multicenter Optimization and Validation of a 2-Gene mRNA Urine Test for Detection of Clinically Significant Prostate Cancer before Initial Prostate Biopsy
Alexander Haese et al.
JOURNAL OF UROLOGY (2019)
MP24-02 CLINICAL UTILITY OF CONFIRMMDX FOR PROSTATE CANCER IN A COMMUNITY UROLOGY PRACTICE
Paul Yonover* et al.
JOURNAL OF UROLOGY (2019)
Second Reply to Letter to the Editor re: Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting
Jay White et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2019)
Detection of the Prostate Cancer Biomarker PCA3 with Electrochemical and Impedance-Based Biosensors
Juliana Coatrini Soares et al.
ACS APPLIED MATERIALS & INTERFACES (2019)
Clinically significant Prostate Cancer diagnosed using a urinary molecular biomarker-based risk score: two case reports
Pieter Minnee et al.
BMC UROLOGY (2019)
A Multicentre Evaluation of the Role of the Prostate Health Index (PHI) in Regions with Differing Prevalence of Prostate Cancer: Adjustment of PHI Reference Ranges is Needed for European and Asian Settings
Peter K-F Chiu et al.
EUROPEAN UROLOGY (2019)
Urinary Molecular Biomarker Test Impacts Prostate Biopsy Decision Making in Clinical Practice
Neal Shore et al.
UROLOGY PRACTICE (2019)
Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting
Jay White et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2018)
The Stockholm-3 Model for Prostate Cancer Detection: Algorithm Update, Biomarker Contribution, and Reflex Test Potential
Peter Strom et al.
EUROPEAN UROLOGY (2018)
Prostate Cancer Diagnostics Using a Combination of the Stockholm3 Blood Test and Multiparametric Magnetic Resonance Imaging
Henrik Gronberg et al.
EUROPEAN UROLOGY (2018)
A Multi-Institutional Prospective Trial Confirms Noninvasive Blood Test Maintains Predictive Value in African American Men
Sanoj Punnen et al.
JOURNAL OF UROLOGY (2018)
Incorporating Biomarkers into the Primary Prostate Biopsy Setting: A Cost-Effectiveness Analysis
Niranjan J. Sathianathen et al.
JOURNAL OF UROLOGY (2018)
Reply to 'Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting'
Behfar Ehdaie et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10 ng/ml at Initial Biopsy
James McKiernan et al.
EUROPEAN UROLOGY (2018)
Cost-Effectiveness of Urinary Biomarker Panel in Prostate Cancer Risk Assessment
Tim M. Govers et al.
JOURNAL OF UROLOGY (2018)
Optimizing patient's selection for prostate biopsy: A single institution experience with multi-parametric MRI and the 4Kscore test for the detection of aggressive prostate cancer
Sanoj Punnen et al.
PLOS ONE (2018)
Reply to Letter to the Editor re: 'Clinical utility of the Prostate Health Index (phi) for biopsy decision management in a large group urology practice setting'
Jay White et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2018)
Diagnostic performance of PCA3 and hK2 in combination with serum PSA for prostate cancer
Zujie Mao et al.
MEDICINE (2018)
Balancing Overdiagnosis and Early Detection of Prostate Cancer using the Stockholm-3 Model
Tobias Nordstrom et al.
EUROPEAN UROLOGY FOCUS (2018)
The Stockholm-3 (STHLM3) Model can Improve Prostate Cancer Diagnostics in Men Aged 50-69 yr Compared with Current Prostate Cancer Testing
Martin Eklund et al.
EUROPEAN UROLOGY FOCUS (2018)
Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions
R. J. Hendriks et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2017)
Evaluating the Four Kallikrein Panel of the 4Kscore for Prediction of High-grade Prostate Cancer in Men in the Canary Prostate Active Surveillance Study
Daniel W. Lin et al.
EUROPEAN UROLOGY (2017)
PCA3 AS a grade reclassification predictor
Annette Fenner
NATURE REVIEWS UROLOGY (2017)
A urinary biomarker-based risk score correlates with multiparametric MRI for prostate cancer detection
Rianne J. Hendriks et al.
PROSTATE (2017)
Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients
Mohammed Alshalalfa et al.
ONCOTARGET (2017)
Association Between Combined TMPRSS2: ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer
Martin G. Sanda et al.
JAMA ONCOLOGY (2017)
Prostate Health Index density improves detection of clinically significant prostate cancer
Jeffrey J. Tosoian et al.
BJU INTERNATIONAL (2017)
A Systematic Review and Meta-analysis of the Diagnostic Accuracy of Prostate Health Index and 4-Kallikrein Panel Score in Predicting Overall and High-grade Prostate Cancer
Giorgio Ivan Russo et al.
CLINICAL GENITOURINARY CANCER (2017)
The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years
Martin Boegemann et al.
BJU INTERNATIONAL (2016)
Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment
Scott A. Tomlins et al.
EUROPEAN UROLOGY (2016)
Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score
Leander Van Neste et al.
EUROPEAN UROLOGY (2016)
Clinical Use of PCA3 and TMPRSS2:ERG Urinary Biomarkers in African-American Men Undergoing Prostate Biopsy
Allison H. Feibus et al.
JOURNAL OF UROLOGY (2016)
Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies
Leander Van Neste et al.
PROSTATE (2016)
The Prostate Health Index Its Utility in Prostate Cancer Detection
Abbey Lepor et al.
UROLOGIC CLINICS OF NORTH AMERICA (2016)
A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy
James McKiernan et al.
JAMA ONCOLOGY (2016)
Assessment of long-term outcomes associated with urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion at repeat biopsy
Selin Merdan et al.
CANCER (2015)
A Multi-institutional Prospective Trial in the USA Confirms that the 4Kscore Accurately Identifies Men with High-grade Prostate Cancer
Dipen J. Parekh et al.
EUROPEAN UROLOGY (2015)
Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer
Tobias Nordstrom et al.
EUROPEAN UROLOGY (2015)
The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation
Amanda Nicholson et al.
HEALTH TECHNOLOGY ASSESSMENT (2015)
Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naive Men
Claire de la Calle et al.
JOURNAL OF UROLOGY (2015)
Prosbiotate: A Multicenter, Prospective Analysis of Infectious Complications after Prostate Biopsy
Franck Bruyere et al.
JOURNAL OF UROLOGY (2015)
The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer
Stacy Loeb et al.
JOURNAL OF UROLOGY (2015)
Prostate cancer screening in men aged 50-69 years (STHLM3): a prospective population-based diagnostic study
Henrik Gronberg et al.
LANCET ONCOLOGY (2015)
Accuracy of the Prostate Health Index Versus the Urinary Prostate Cancer Antigen 3 Score to Predict Overall and Significant Prostate Cancer at Initial Biopsy
Thomas Seisen et al.
PROSTATE (2015)
The Added Value of Percentage of Free to Total Prostate-specific Antigen, PCA3, and a Kallikrein Panel to the ERSPC Risk Calculator for Prostate Cancer in Prescreened Men
Moniek M. Vedder et al.
EUROPEAN UROLOGY (2014)
Prospective Multicentre Evaluation of PCA3 and TMPRSS2-ERG Gene Fusions as Diagnostic and Prognostic Urinary Biomarkers for Prostate Cancer
Gisele H. J. M. Leyten et al.
EUROPEAN UROLOGY (2014)
Can Urinary PCA3 Supplement PSA in the Early Detection of Prostate Cancer?
John T. Wei et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Clinical Validation of an Epigenetic Assay to Predict Negative Histopathological Results in Repeat Prostate Biopsies
Alan W. Partin et al.
JOURNAL OF UROLOGY (2014)
Urinary PCA3 as a Predictor of Prostate Cancer in a Cohort of 3,073 Men Undergoing Initial Prostate Biopsy
K. Kent Chevli et al.
JOURNAL OF UROLOGY (2014)
Nationwide Population Based Study of Infections after Transrectal Ultrasound Guided Prostate Biopsy
Karl-Johan Lundstrom et al.
JOURNAL OF UROLOGY (2014)
The Prostate Health Index: a new test for the detection of prostate cancer
Stacy Loeb et al.
THERAPEUTIC ADVANCES IN UROLOGY (2014)
Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy
Atsushi Ochiai et al.
BJU INTERNATIONAL (2013)
Value of PCA3 to Predict Biopsy Outcome and Its Potential Role in Selecting Patients for Multiparametric MRI
Gisele H. J. M. Leyten et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)
Clinical Utility of an Epigenetic Assay to Detect Occult Prostate Cancer in Histopathologically Negative Biopsies: Results of the MATLOC Study
Grant D. Stewart et al.
JOURNAL OF UROLOGY (2013)
Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer
Simpa S. Salami et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2013)
PCA3 sensitivity and specificity for prostate cancer detection in patients with abnormal PSA and/or suspicious digital rectal examination. First Latin American experience
Christian G. Ramos et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2013)
Defining prostate cancer risk before prostate biopsy
Raj P. Pal et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2013)
Preoperative Prostate-Specific Antigen Isoform p2PSA and Its Derivatives, %p2PSA and Prostate Health Index, Predict Pathologic Outcomes in Patients Undergoing Radical Prostatectomy for Prostate Cancer
Giorgio Guazzoni et al.
EUROPEAN UROLOGY (2012)
Critical Assessment of Preoperative Urinary Prostate Cancer Antigen 3 on the Accuracy of Prostate Cancer Staging
Marco Auprich et al.
EUROPEAN UROLOGY (2011)
Prostate-Specific Antigen (PSA) Isoform p2PSA Significantly Improves the Prediction of Prostate Cancer at Initial Extended Prostate Biopsies in Patients with Total PSA Between 2.0 and 10 ng/ml: Results of a Prospective Study in a Clinical Setting
Giorgio Guazzoni et al.
EUROPEAN UROLOGY (2011)
The diagnostic value of PCA3 gene-based analysis of urine sediments after digital rectal examination for prostate cancer in a Chinese population
Mo Shen et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2011)
A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range
William J. Catalona et al.
JOURNAL OF UROLOGY (2011)
Urinary PCA3 Score Predicts Prostate Cancer Multifocality
Virginie Vlaeminck-Guillem et al.
JOURNAL OF UROLOGY (2011)
Prostate-Specific Antigen (PSA) Isoform p2PSA in Combination with Total PSA and Free PSA Improves Diagnostic Accuracy in Prostate Cancer Detection
Flip H. Jansen et al.
EUROPEAN UROLOGY (2010)
Performance of Prostate Cancer Antigen 3 (PCA3) and Prostate-Specific Antigen in Prescreened Men: Reproducibility and Detection Characteristics for Prostate Cancer Patients with High PCA3 Scores (≥100)
Monique J. Roobol et al.
EUROPEAN UROLOGY (2010)
PCA3 Molecular Urine Test for Predicting Repeat Prostate Biopsy Outcome in Populations at Risk: Validation in the Placebo Arm of the Dutasteride REDUCE Trial
Sheila M. J. Aubin et al.
JOURNAL OF UROLOGY (2010)
Predictive Value of PCA3 in Urinary Sediments in Determining Clinico-Pathological Characteristics of Prostate Cancer
Daphne Hessels et al.
PROSTATE (2010)
A [-2]proPSA-Based Artificial Neural Network Significantly Improves Differentiation Between Prostate Cancer and Benign Prostatic Diseases
Carsten Stephan et al.
PROSTATE (2009)
Under diagnosis and over diagnosis of prostate cancer
Theresa Graif et al.
JOURNAL OF UROLOGY (2007)
PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy
Leonard S. Marks et al.
UROLOGY (2007)
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer
SA Tomlins et al.
SCIENCE (2005)
DD3PCA3-based molecular urine analysis for the diagnosis of prostate cancer
D Hessels et al.
EUROPEAN UROLOGY (2003)
Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging
WJ Catalona et al.
UROLOGY (2000)
分享论文
